Skip to main content

Angel García Jiménez

Institutions of which they are part

Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Angel García Jiménez

Institutions of which they are part

Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Identificación de nuevos factores pronóstico y diagnóstico en cáncer basados en microRNAs y sus proteínas diana que se asocian a tumores de carácter más agresivo

IP: Matilde Lleonart Pajarin
Collaborators: Angel García Jiménez, Teresa Moline Marimon, Carmela Iglesias i Felip, Vicente Peg Camara
Funding agency: Instituto de Salud Carlos III
Funding: 145200
Reference: PI12/01104
Duration: 01/01/2013 - 30/06/2017

Identificación de perfiles de microRNAs (miRNAs) asociados a corta o larga supervivencia en pacientes con cáncer de ovario avanzado, para mejorar la eficacia del tratamiento

IP: Jaume Reventós Puigjaner
Collaborators: Angel García Jiménez, Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Fundació Santiago Dexeus Font
Funding: 6000
Reference: DEXEUS-B29/012
Duration: 25/01/2013 - 25/01/2015

Red Temática de Investigación Cooperativa en Cáncer (RTICC)

IP: Santiago Ramon y Cajal Agüeras
Collaborators: Cleofé Romagosa Pérez-Portabell, Maria Rosa Somoza Lopez de Haro, Angel García Jiménez, Roso Marès Pagès, Teresa Moline Marimon, Josep Castellví Vives, Pere Barba Suñol, Javier Hernandez Losa, Marta Sese Faustino, Vicente Peg Camara, Stefania Landolfi , Trond Aasen
Funding agency: Instituto de Salud Carlos III
Funding: 209700
Reference: RD12/0036/0057
Duration: 01/01/2013 - 30/06/2017

Caracterización del proceso de metástasis y diseño de nuevas estrategias terapéuticas en el cáncer de endometrio: modelos in vivo

IP: Antonio Gil Moreno
Collaborators: Angel García Jiménez, Berta Diaz Feijoo, Silvia Cabrera Diaz
Funding agency: Instituto de Salud Carlos III
Funding: 39022.5
Reference: PI11/01350
Duration: 01/01/2012 - 30/09/2015

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

Consuelo Pedrós Cholvi

Consuelo Pedrós Cholvi

Clinical Pharmacology
Read more
Cristina Vetoret Vázquez

Cristina Vetoret Vázquez

Research assistant
Clinical Neuroimmunology
Read more
Melissa Bradbury Lobato

Melissa Bradbury Lobato

Biomedical Research in Gynaecology
Read more
Norberto Núñez Seral

Norberto Núñez Seral

Tècnic/a Superior Recerca
High Technology Unit (UAT)
Preclinical Core Facilities
Core Facilities Area
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.